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Castration-resistant prostate cancer is the lethal condition suffered by prostate 
cancer patients that become refractory to androgen deprivation therapy. EPI-001 
is a recently identified compound active against this condition that modulates the 
activity of the androgen receptor, a nuclear receptor that is essential for disease 
progression. The mechanism by which this compound exerts its inhibitory activity 
is however not yet fully understood. Here we show, by using high resolution 
solution nuclear magnetic resonance spectroscopy, that EPI-001 selectively 
interacts with a partially folded region of the transactivation domain of the 
androgen receptor, known as transactivation unit 5, that is key for the ability of 
prostate cells to proliferate in the absence of androgens, a distinctive feature of 
castration-resistant prostate cancer. Our results can contribute to the 
development of more potent and less toxic novel androgen receptor antagonists 
for treating this disease. 
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INTRODUCTION 
 
Prostate cancer (PC) is the second most common cancer in men and can be cured by 
surgery or radiotherapy in ca 70% of cases. The first line of pharmacological treatment 
for the remaining cases targets the androgen receptor (AR) because prostate cells 
depend on its activation by androgens for their growth and proliferation1. Activation can 
be prevented by combining androgen deprivation therapy, which inhibits the secretion of 
androgens by the testes, with the administration of antagonists that competitively bind to 
the binding site of androgens in the ligand-binding domain (LBD) of AR2. 
 
Two to three years into this treatment PC patients inevitably develop castration-resistant 
prostate cancer (CRPC) as prostate cancer cells acquire the ability to activate AR at low 
levels of circulating androgens and in the presence of antagonists3. The mechanisms of 
aberrant activation are not well understood but appear to include the amplification of the 
AR gene and AR overexpression, the expression of constitutively active AR splice 
variants lacking the LBD, cell signaling cross-talk and mutations in both AR and 
transcriptional co-regulators4. 
 
AR is a large multi-domain protein composed of globular ligand- and DNA-binding 
domains (LBD and DBD) and an N-terminal transactivation domain (NTD) that is 
intrinsically disordered (ID)5,6 (Fig. 1a). The function of the NTD (residues 1 to 558) is to 
recruit the basal transcription machinery by binding to general transcription factors either 
directly or assisted by transcriptional co-activators1. These protein-protein interactions 
are thought to cause the folding of binding motifs in a region of the NTD called activation 
function 1 (AF-1) that has not yet been characterized at high resolution (Fig. 1a,b)6. 
Inhibiting these interactions is considered a potential therapeutic approach for both PC 
and CRPC7, but the NTD has not been considered a suitable target for drug discovery 
due to its apparent lack of persistent secondary and tertiary structure. 
 
The development of drugs that interact with ID regions has however recently been met 
with some success8,9, and has shown that targeting them with small molecules may be a 
viable therapeutic approach10,11. A particularly important development in this area was 
the recent discovery of EPI-001, an experimental drug for the treatment of CRPC 
identified by phenotypic screening that is efficacious both in cell lines and in an animal 
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model of this disease12. In vivo EPI-001 binds irreversibly to the AR NTD and weakens 
its interaction with general transcription factors and transcriptional co-activators13. 
 
The discovery of EPI-001 represents an important milestone and a derivative of this 
compound is currently in clinical trials for CRPC (NCT02606123). The lack of a detailed 
understanding of the structural features of the domain and of the mechanism of action of 
this class of compounds represents, however, a hurdle for the rational design of 
optimized inhibitors. Here we reveal, by using solution nuclear magnetic resonance 
(NMR) spectroscopy,  the structural properties of the ID regions of the NTD predicted to 
have a high propensity to fold and show that  EPI-001 targets a region of sequence, 
known as transcription activation unit 5 (Tau-5), that is key for the ability of prostate cells 
to proliferate in the absence of androgens. 
 
METHODS 
 
Protein expression and purification The DNA sequences coding for human WT AR 
residues 265 to 340 (AF-1*265-340), 330 to 448 (Tau-5*) and 142 to 448 (AF-1*) were 
cloned into Gateway pDEST17 vectors (Invitrogen) with an N-terminal His6-tag and a 
TEV cleavage site. Transformed E. coli Rosetta cells were grown at 37°C in LB medium 
for the production of non-isotopically labeled protein. For single (15N) or double (15N,13C) 
isotopic labeling, cells were grown in minimal MOPS medium14 containing 15NH4Cl or 
15NH4Cl and 13C-glucose, respectively. The AF-1* fusion protein accumulated in 
inclusion bodies which were solubilized in lysis buffer containing 8 M urea and 
fragmented by a pass through a cell disruptor at 25 kpsi. The fusion protein was purified 
by Ni2+ affinity chromatography in urea, which was removed by two dialysis steps, after 
which the His6-tag was cleaved by the TEV protease. The cleaved AF-1* was further 
purified by reverse Ni2+ affinity and size exclusion chromatography in 20 mM sodium 
phosphate buffer with 1 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP) at pH 
7.4.  
 
Peptides The synthesis of peptides R1, R2 and R3 (See SI)  was performed by solid 
phase peptide synthesis by GenScript (peptide R1) or by ICTS NANBIOSIS, more 
specifically by the peptide synthesis unit of the CIBER in bioengineering, biomaterials & 
nanomedicine (CIBER-BBN) at the Barcelona science park (peptides R2 and R3). The 
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lyophilized peptides were dissolved in deionized water and the pH of the resulting 
solution was adjusted by addition of a concentrated NaOH solution. The concentration of 
these solutions was determined by amino acid analysis. The absence of intermolecular 
disulfide bonds in the R2 peptide, which contains one Cys residue, was confirmed by 
mass spectrometry (MS). 
 
Chemical synthesis of EPI-001 and stereoisomers EPI-001 contains two stereogenic 
centers and can therefore be found as two pairs of enantiomers. We synthesized the 
four isomers with high diastereo- and enantioselectivity (Chiral HPLC). The synthesis 
followed the sequence detailed in Fig. S1 of the SI.  Bisphenol A was  treated with 
enantiomerically pure glycidol. The resulting diol was protected as dimethyl acetal and 
the free phenol was allowed to react with another isomer of glycidol.  The corresponding 
diol was transformed into the epoxide and opened with CeCl3. The treatment gave the 
final product by concomitant deprotection of the acetal. Full experimental details as well 
as the complete characterization of all isomers can be found in the SI. 
 
NMR The assignment of AF-1* was obtained by using a divide and conquer approach. 
The resonances of fragments AF-1*265-340, Tau-5* (330 to 448) and AF-1* (142-448)  
were obtained by analyzing conventional three-dimensional triple resonance 
experiments acquired with standard Bruker pulse sequences on Bruker 600 MHz and 
800 MHz  spectrometers at 278 K in 20 mM sodium phosphate buffer with 1 mM TCEP 
at pH 7.4. The resonances of AF-1*265-340 and Tau-5* were equivalent to those of AF-1*, 
except for residues near the termini (Fig. S2), and allowed transferring the assignments 
from the former to the latter; the residues that were unique to AF-1* were assigned 
directly by analysis of the relevant spectra. To measure the perturbations caused by 
EPI-001, EPI-002, EPI-003, EPI-004 and EPI-005 (details available as SI) on the 
resonances of AF-1* appropriate volumes of a 50 mM stock solution of these 
compounds in 100% dioxane-d8 were added to aliquots containing 25 µM AF-1*, 20 mM 
sodium phosphate, 1 mM TCEP, 10% D2O, 30 µM DSS-d6 at pH 7.4. 
 
RESULTS AND DISCUSSION 
 
As previously reported5,6,15 the sequence of the NTD has features typically encountered 
in ID regions16. It has a high content of Gly, Pro, polar and charged residues and, as 
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shown in figure 1b, possesses regions of low sequence complexity such as polyGln 
(residues 58-78, 84-89, 193-197), polyPro (372-379), polyAla (398-402) and polyGly 
(449-472) tracts. Such disordered tracts are commonly flanked by motifs of relatively low 
disorder propensity, with some helical propensity and rich in hydrophobic side chains, 
that are often involved in interactions with binding partners17. An analysis of the 
sequence of the NTD with predictors of disorder and helical propensity indicates that 
several such motifs are indeed present in the domain and it has been proposed that they 
may correspond to the regions of sequence recognized by general transcription factors 
and transcriptional co-regulators15 (Fig. 1c,d,e). 
 
A number of studies have aimed at identifying the regions of sequence of AF-1 that are 
essential for transcriptional activity18,19. Two large regions of sequence, known as 
transcription activation units 1 and 5 (Tau-1, 102-371 and Tau-5, 361-537) have 
emerged as especially important (Fig. 1b). Tau-1 is crucial for the transcriptional activity 
of AR when the receptor is activated by androgens18. Although Tau-5 is less well 
characterised, it has been shown to be more important than Tau-1 when activation 
occurs via androgen independent mechanisms in androgen depletion independent cell 
lines derived from CRPC patients and mouse xenograft models of PC20,21. Efforts have 
also been directed at identifying the critical stretches of residues within these regions 
and suggest that for Tau-1 they correspond to residues 174 to 204  (core Tau-1)19, and 
for Tau-5 to residues 433 to 437 (WHTLF motif)20 (Fig. 1c). 
 
AF-1* is partially folded To investigate the structural properties of the NTD and its 
interaction with EPI-001 we cloned, expressed, purified and studied by NMR at 278K a 
308-residue construct (AF-1*, residues 142-448) containing the part of AF-1 predicted to 
have a low disorder propensity (Fig. 1b and 1c), that is flanked by polyGln and polyGly 
tracts (Fig. 1b). In agreement with previous reports based on the use of other biophysical 
methods6 the 1H,15N-HSQC spectrum of AF-1* had the features expected in an ID region 
such as low HN chemical shift dispersion (Fig. 2a). In addition, and contrary to what is 
the case for NTD constructs containing residues 1 to 141, which include the polyQ tract 
(Fig. 1b), this region of the NTD was sufficiently stable to allow a characterization of its 
structural properties by solution NMR.  
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In spite of its ID nature, the AF-1 region of the NTD has been shown to have helical 
propensity by circular dichroism (CD) in buffer and in the presence of cosolvents that 
stabilize intramolecular hydrogen bonds, as well as in the presence of the natural 
osmolyte  trimethylamine oxide (TMAO)5,22. To identify the regions of sequence that 
adopt this secondary structure we assigned the resonances of AF-1* by a divide and 
conquer approach (see Methods), compared the Cα and Cβ chemical shifts, which are 
reliable reporters of secondary structure, to those predicted for disordered AF-1* (Fig. 
2b)23 and used the SSP algorithm of Forman-Kay and co-workers24 to quantify the 
secondary structure propensity for the various residues of this construct from analysis of 
the backbone (13Cα, 13Cβ, 13CO, 15N, HN) chemical shifts.  
 
The results that we obtained indicated the presence of two regions of high helical 
propensity (defined as ΔδCα-ΔδCβ > 1 ppm and SSP ≈ 0.5, corresponding to a helical 
propensity of 50%) which correspond to residues 185-200, in Tau-1, and 390-410, in Tau-5. 
Other regions of intermediate helical propensity (defined as ΔδCα-ΔδCβ ≈ 0.5 ppm and SSP ≈ 
0.2) could be also identified, such as the region 230-240, in Tau-1, and 355-365 in Tau-5 
(Fig. 2b, c). In addition to identifying regions of helical secondary structure the analysis 
of the chemical shifts also suggests that residues 144-154 and 270-290 of AF-1* adopt 
an extended conformation (ΔδCα-ΔδCβ ≈ -0.5 ppm and SSP ≈ -0.3) (Fig. 2b, c).  
 
To further characterize the structural properties of AF-1* we characterized the dynamics 
of AF-1* by measuring the transverse relaxation rates (R2) of the backbone 15N nuclei. 
Such relaxation rates are good reporters of nascent secondary structure and transient 
tertiary contacts in chemically denatured and ID proteins 25. The results that we 
obtained, presented in figure 2d, indicate that the regions with nascent secondary 
structure revealed by the analysis of the 13C chemical shifts (Fig. 2b) also display 
relatively high R2 values. These are especially high, reaching values of ca 15 s-1, for 
three regions of sequence found in Tau-5 predicted to have low disorder propensity 26 
and presenting, in two cases, high helical propensity.  
 
Some of the regions of sequence that we identified as partially folded in AF-1* 
correspond in fact to the epitopes of binding partners of AR or are known to be important 
for the function of this receptor. In Tau-1, for example, the region that is most structured 
corresponds to core Tau-1 (Fig. 2b). This region encompases the motif 
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183LSEASTMQLL192, which is the binding epitope of TAB2, a component of the NCoR co-
repressor complex27. Partially folded residues 144 to 154, also in Tau-1, are part of the 
binding epitope of the amino-terminal bromodomains of BRD4 28. The region containing 
residues 230 to 240, of intermediate helicity, overlaps with the binding site of CHIP, a 
protein known to recruit the chaperone machinery by interaction with Hsc70, Hsp70 and 
Hsp90, which mediates the degradation of AR by the proteasome 29 (Fig. 1e).  
 
In Tau-5 the regions that we found to be partially folded are separated by motifs of low 
sequence complexity such as the Pro-rich region 371GPPPPPPPPHP381 and the Gly-rich 
region 414GAGAAGPGSGSPS426. The former has been proposed to be the binding site 
of the SH3 domain of Src 30 and the latter harbors a phosphosite, S424, which is thought 
to be important for transcriptional activity 31. Although we have not  assigned the 
backbone resonances corresponding to the Pro residues in this Pro-rich motif, an 
analysis of the secondary chemical shifts of residues in its flanking regions (367-370, 
385-388, Fig. 2b) suggests that it may adopt an extended conformation, likely of the 
polyproline II type, given the high Pro content; the polyproline II conformation is rather 
unusual but has been documented for several other IDPs.32 The chemical shifts and 
transverse 15N relaxation rates of the Gly-rich region (414-426, Fig. 2b,c,d ) indicate, by 
contrast, that it is disordered, as expected due to its high Gly content. 
 
No binding partners have yet been identified for regions 355-365 and 390-410, that are 
partially helical, but the 433WHTLF437 motif in region 433-447, corresponding to the core 
of Tau-5, has been proposed to bind both to activation function 2 (AF-2) in the LBD of 
androgen-bound AR 33,34 and to histone acetyltransferase p30035; in addition it has been 
shown to be indispensable for transcriptional activity in androgen depletion independent 
cell lines20. 
 
We noted that the helical propensity of the partially folded regions identified in both Tau-
1 and Tau-5 (SSP ≈ 0.5, corresponding to a population of helix of ca 50%) is 
substantially higher than that predicted by algorithms that solely consider local 
interactions such as Agadir 36 (Figs. 1e and 2b, c), indicating that non-local interactions 
may contribute to stabilizing the secondary structure.  We thus investigated whether 
such non-local interactions included intramolecular contacts between residues in Tau-1 
and Tau-5, similarly to what has been shown to occur in globular proteins under mild 
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denaturing conditions37. For this analysis we used an NTD construct encompassing the 
part of Tau-5 contained in AF-1*, corresponding to residues 330-448 (termed Tau-5*, 
Fig. 1b). We compared the HN and 15N chemical shifts of Tau-5* to those of AF-1* and 
observed that they were highly similar (Fig. S2). These results indicate that the chemical 
environment that residues in the Tau-5 region experience is the same both in the 
presence and absence of Tau-1. We conclude that the secondary structure present in 
AF-1* does not rely on long-range interactions between residues in Tau-1 and residues 
in Tau-5. 
                                         
EPI-001 interacts reversibly with Tau-5 It has been proposed that the mechanism of 
action of EPI-001 (Fig. 3a) involves two steps13. The first step being the formation of a 
reversible complex between this compound and a specific conformation of AF-1 and the 
second the nucleophilic attack, by a protein side chain, on the C-Cl bond of EPI-001 to 
form an adduct unable to activate transcription. To investigate the first step of this 
mechanism and characterize the putative reversible complex we synthesized EPI-001 
(details available as SI) and used NMR to analyze its effect on the resonances of AF-1* 
at 278 K. As shown by MS under these conditions the irreversible reaction of EPI-001 
with AF-1* is sufficiently slow to allow the study of the reversible interaction by NMR 
(Fig. S5). 
 
The results that we obtained, shown in figures 3b and c, indicate that EPI-001 causes 
small but highly reproducible changes in 15N chemical shifts in residues 354 to 448 of 
AF-1*, that correspond to Tau-5. Interaction with EPI-001 affects the resonances of a 
large number of residues, which are found in the three regions of sequence in Tau-5 
identified as partially folded by the combined analysis of the backbone 13C chemical 
shifts and 15N transverse relaxation rates (Figs. 2b, 2d and 3b). We detected much 
smaller perturbations of the resonances of residues corresponding to Tau-1 even though 
this region contains partially helical regions such as residues in core Tau-1 (Figs. 2b and 
3b). These results indicate that EPI-001 does not simply interact with any region of 
sequence with helical propensity but, rather, that this compound targets Tau-5 due to 
the ability of this sub-domain to adopt a conformation or, most likely, an ensemble of 
conformations that have affinity for it. 
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With the aim of further investigating the nature of the interaction we monitored the effect 
of AF-1* on the resonances of EPI-001. We observed that sub-stoichiometric amounts 
(25 µM and 50 µM) of AF-1* caused small but reproducible chemical shift changes in the 
1H NMR spectrum of EPI-001 at 250 µM, as well as increases in linewidth similar to 
those commonly observed in small drug-like molecules transiently associating with 
macromolecules (Fig. S3). Together with our observation of perturbations in a large 
number of  residues of AF-1* this result suggests that EPI-001 interacts with an 
ensemble of conformations adopted by AF-1* where these regions of sequence adopt a 
partially folded structure.  
 
A large number of residues in Tau-5 experience chemical shift perturbations, more than 
what is expected for the binding of a small molecule. This can be due to the inspecific 
interaction of one or various molecules of EPI-001 with three independent interaction 
sites or to the combination of direct and indirect chemical shift changes due to structural 
changes occurring in Tau-5 upon interaction with EPI-00138. To exclude that one or more 
EPI-001 molecules interact independently with the three regions of sequence of AF-1* 
where chemical shift perturbations are observed we monitored the effect on its 1H NMR 
spectrum of adding three peptides (R1 to R3) with sequences corresponding to regions 
341-371, 391-414 and 426-446, respectively (details available as SI). We found that 
these peptides caused no changes in the spectrum of EPI-001, indicating that EPI-001 
does not interact with them (Fig. S3) and confirming that residues 354-448 must 
simultaneously be present because they are necessary for binding this compound or for 
stabilizing the bound state of Tau-5* (Fig. 4). 
 
It is interesting to note that Tau-5, the region of sequence of the NTD targeted by EPI-
001, is partially folded, but it is important to emphasize that the data that we have 
obtained do not provide us with a mechanism of molecular recognition. It is possible that 
a conformational selection mechanism operates i.e. that  EPI-001 interacts with a subset 
of the conformations that Tau-5* samples in equilibrium, but also that EPI-001 induces a 
new conformation in Tau-5*. Further work will be necessary to differentiate these two 
scenarios.  
 
EPI-001 has two stereogenic centers and can therefore be found as four stereoisomers. 
To investigate whether the interaction between this compound and Tau-5 is 
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stereospecific we synthesized the four stereoisomers (details available as SI) and 
studied their interaction with AF-1* by NMR. The results that we obtained (Fig. S4) 
indicate that the four compounds can interact with the NTD of AR, and thus the 
interaction appears to occur with little or no stereoselectivity. These results are in 
agreement with results obtained in vivo by Myung et al, who found that, although one of 
the stereoisomers tested was slightly more active than the other ones, the inhibitory 
activity of the four stereoisomers was similar.13 
 
Put together our results indicate that AF-1 is partially folded in regions of sequence that 
correspond to those which are functionally relevant for interacting with the transcription 
machinery and co-regulators of transcription. In addition, they reveal that Tau-1 and Tau-
5, the two independent transcription activation units that are found in AF-1, correspond 
to different sub-domains that appear not to be involved in long-range interactions i.e. are 
structurally and dynamically, at least under our conditions, independent. Finally, and 
most importantly, they show that Tau-5, that plays a particularly important role in AR 
activation in the absence of androgens, can be targeted by compounds such as EPI-001 
(Fig. 4). Although the lack of stereoselectivity that we observe suggests that the binding 
mode of EPI-001 may not be sufficiently well-defined for conventional drug development 
our results are of relevance for drug discovery for CRPC because they suggests that the 
NTD, and Tau-5 in particular, may represent a suitable therapeutic target.  
 
ACKNOWLEDGEMENTS 
 
We thank J. M. Valverde (IRB) as well as the NMR facilities of the University of 
Barcelona (CCiT UB) and the Instituto de Química Física Rocasolano (IQFR, CSIC) for 
their assistance in, respectively, protein production and NMR. This work was supported 
by IRB, ICREA (X.S.), Obra Social “la Caixa” (Fellowship to E.D.M. and CancerTec 
grants to X.S.) MICINN (CTQ2009-08850 to X.S.), MINECO (BIO2012-31043 to X.S.; 
CTQ2014-56361-P to A.R), Marató de TV3 (102030 to X.S. and 102031 to E.E.P) the 
COFUND programme of the European Commission (C.T.W.P., A. R. and X.S.), the 
European Research Council (CONCERT, contract number 648201, to X.S.), the Ramón 
y Cajal program of MICINN (RYC-2011-07873 to C.W.B.) the Serra Hunter Programme 
(E.E.P.) and AGAUR (SGR-2014-56RR14 to E.E.P). IRB Barcelona is the recipient of a 
Severo Ochoa Award of Excellence from MINECO (Government of Spain). 
12 
 
Supporting Information Available: This material is available free of charge via the 
Internet 
  
13 
 
FIGURE LEGENDS 
 
Figure 1 Predicted properties of the sequence of the transactivation domain of AR a) 
Domain organization of AR 34,39 with an indication of the position of Zn atoms in the DBD 
(grey) and of dihydrotestosterone (DHT) in the LBD (blue). b) Definitions of activation 
function 1 (AF-1), transcription acctivation units 1 and 5 (Tau-1 and Tau-5), AF-1* and 
Tau-5* (the regions of sequence studied in this work) with an indication of the regions of 
low sequence complexity such as polyGln (Qn), polyPro (Pn), polyAla (An) and polyGly 
(Gn) tracts. c) Propensity to disorder of the NTD predicted by PONDR VL-XT26 with an 
indication of the functional motifs defining the core of Tau-1 and Tau-5, shaded in red 
and of the region of sequence studied in this work, shaded in grey. d) Positions of the 
motifs of the NTD of AR involved in protein protein interactions and acronyms of the 
binding partners (see main text for details). e) Propensity to adopt α-helical 
conformations predicted by Agadir 36, as a function of residue number, with an indication 
of the core of Tau-1 and Tau-5 (shaded in red) and AF-1* (shaded in grey).  
 
Figure 2 Structural properties of the transactivation domain revealed by solution NMR a) 
1H,15N-HSQC spectrum of AF-1*. b) Plot of the difference between the secondary Cα 
and Cβ chemical shifts measured for AF-1* with an indication of the regions of sequence 
with predicted disorder propensity (DP) lower than 50%, in grey, with predicted helical 
propensity (hel) higher than 10%, in blue, and involved in protein protein interactions 
(PPIs), in green and, at the bottom of the top panel, an indication of the nascent 
secondary structure identified experimentally (SS, cylinders indicate helical propensity, 
black rectangles indicate propensity to adopt an extended conformation). c) Plot of the 
secondary structure propensity of the residues of AF-1*, where SSP=1 indicates a fully 
formed helix and SSP=1 an extended conformation, obtained by using the algorithm 
SSP to extract the information on secondary structure contained in backbone (13Cα, 
13Cβ, 13CO, 15N, HN) chemical shifts. d) Plot of the 15N transverse relaxation rates (R2) of 
the residues of AF-1* at 250 µM. The cores of Tau-1 and Tau-5 are shaded in red. 
 
Figure 3 EPI-001 selectively interacts with transcription activation unit 5 of the 
transactivation domain of AR a) Structure of EPI-001 with an indication of the two 
stereogenic centres with the symbol *. b) Plot, as a function of residue number, of the 
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change in 15N chemical shift of AF-1* caused by addition of EPI-001. c) Selected regions 
of the 1H,15N-HSQC spectrum of 25 µM AF-1* in the absence (blue) and in the presence 
(red) of 10 molar equivalents of EPI-001. 
 
Figure 4 Scheme of the interaction of EPI-001 with partially folded of Tau-5.  
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